Internal Medicine, Endocrinology, Diabetes, & Metabolism · Hobart, IN
NPI
1356306799
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
6
Hospital affiliations
1600 S Lake Park Ave Ste 1104
Hobart, IN, 46342
Phone (219) 945-0600
Groups this clinician bills Medicare through
Medicare paid, 2024
$170K
2,506 services
Medicare patients, 2024
763
Average age 73
Drug cost, 2024
$4.6M
11,454 prescriptions
Company payments, 2025
$182
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mohamed F Zeitoun was code 99214 (office e&m - established), 1,761 times for 721 patients. In total Mohamed F Zeitoun billed 2,506 services in 5 codes, and Medicare paid $170K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-11-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,761 | 721 | $81.29 | $143K |
| 95251 Test - Miscellaneous | Office | 633 | 88 | $24.91 | $16K |
| 99204 Office E&M - New | Office | 101 | 101 | $101.48 | $10K |
By year: 2022 $172K for 2,358 services; 2023 $162K for 2,285 services; 2024 $170K for 2,506 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mohamed F Zeitoun prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,756 prescriptions and refills. In total Mohamed F Zeitoun wrote 11,454 Medicare prescriptions that cost $4.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,756 | 4,944 | 409 | $15K |
| Glimepiride Generic | 884 | 2,542 | 260 | $6,150 |
| Synthroid Levothyroxine Sodium | 821 | 2,167 | 176 | $70K |
| Metformin Hcl Er Metformin Hcl | 726 | 2,124 | 234 | $5,416 |
| Ozempic Semaglutide | 693 | 1,507 | 176 | $1.4M |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 477 | 1,262 | 185 | $58K |
| Metformin Hcl Generic | 430 | 1,244 | 128 | $2,864 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 417 | 1,106 | 157 | $84K |
| Mounjaro Tirzepatide | 397 | 733 | 83 | $794K |
| Atorvastatin Calcium Generic | 341 | 968 | 101 | $2,924 |
| Humalog Kwikpen U-100 Insulin Lispro | 287 | 725 | 121 | $141K |
| Novolog Mix 70-30 Flexpen Insulin Aspart Prot/Insuln Asp | 251 | 527 | 73 | $107K |
| Losartan Potassium Generic | 195 | 561 | 63 | $1,493 |
| Humalog Mix 75-25 Kwikpen Insulin Lispro Protamin/Lispro | 181 | 469 | 62 | $94K |
| Tresiba Flextouch U-100 Insulin Degludec | 176 | 416 | 51 | $174K |
Brand drugs: 5,377 claims; generic drugs: 5,153 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mohamed F Zeitoun $182 ($182 in general payments such as food, travel and fees) from 4 companies. The largest payer was Novo Nordisk Inc with $96.81.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.